الصفحة الرئيسية>>Signaling Pathways>> Metabolism>> Metabolic Syndrome>>sPLA2 Inhibitor

sPLA2 Inhibitor (Synonyms: KH064, Secretory Phospholipase A2 Inhibitor)

رقم الكتالوجGC44943

مثبط sPLA2 ، أحد مشتقات D-tyrosine ، هو مثبط إفرازي قوي وفعال عن طريق الفم من phospholipase A2 (sPLA2) مع IC50 من 29 نانومتر للإفراز البشري غير البنكرياس PLA2 isoform IIa (hnpsPLA2-IIa).

Products are for research use only. Not for human use. We do not sell to patients.

sPLA2 Inhibitor التركيب الكيميائي

Cas No.: 393569-31-8

الحجم السعر المخزون الكميّة
500μg
60٫00
متوفر
1mg
103٫00
متوفر
5mg
419٫00
متوفر
10mg
756٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Secreted phospholipases A2 (sPLA2s) are a diverse family of low molecular weight PLA2s with tissue-specific expression patterns and actions. The group IIA sPLA2 (sPLA2-IIA) was originally purified from platelets and exudates from patients with rheumatoid arthritis. Its expression can be induced by inflammatory mediators, and mouse studies suggest that it may play roles in colorectal polyposis, atherosclerosis, and bacterial infections. sPLA2 inhibitor is an orally active inhibitor of sPLA2-IIA. It protects against intestinal reperfusion injury in rats when given at 10 mg/kg orally. sPLA2 inhibitor also attenuates NF-κB signaling in lung cancer cells and protects against diet-induced metabolic syndrome in rats.

مراجعات

Review for sPLA2 Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for sPLA2 Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.